AXSM - Axsome Therapeutics Future Price to Earnings
Axsome Therapeutics (AXSM) maintains an impeccable reputation as a developer of effective neurological drugs. The company's forward P/E ratio visualizes the transition of these achievements into innovative therapies for depression and migraine, where the level of 38.30 determines this valuation. Business development is further complemented by the implementation of robotic packaging lines and digital automation for clinical trial data analysis.
Summary analytical data breakdowns for Axsome Corp (AXSM)
- current price and projected stock value:
- market capitalization statistics:
- balance sheet equity data:
- debt and liquidity details:
Total Debt to Capital Axsome Therapeutics|AXSM - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Axsome Therapeutics|AXSM - Aggregate Debt Obligations|Debt to Book Value Axsome|AXSM - Amount of Long-Term Liabilities|Company Short-Term Debts Axsome Therapeutics|Quick Ratio axsome.com
- company profitability and valuation multiples indicators:
AXSM - Company Net Income|Expected Profit Axsome Therapeutics|AXSM - Company Value to Net Income|Forward P/E Multiple Axsome Therapeutics Inc|AXSM - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Axsome|AXSM - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) Axsome Therapeutics|AXSM - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months axsome.com|AXSM - Earnings growth in current year|Expected earnings per share growth for next year Axsome Therapeutics
Fundamental valuation:Axsome Therapeutics, Inc. AXSM
The business vulnerability to market shocks is offset by the competencies of the Axsome Therapeutics (AXSM) team, whose ability to scale commercial drug launches creates a fundamental margin of safety. Analyzing the company's forward P/E for the coming year, an investor assesses the value of future earnings through the lens of consensus forecasts, where identifying local bottoms on the chart allows for entry into the asset before the start of a bullish trend.
Key competitors
Projected Price to Earnings BIIB (Biogen)|Neurocrine - Price to Future Earnings Ratio|Future Price to Earnings Regencell RGC|Market Cap to Projected Earnings ACADIA Corp (ACAD)|XENE - Future Price to Earnings|Projected Price to Earnings Ratio vikingtherapeutics.com|Supernus (SUPN) - Future Price to Earnings|Projected Price to Earnings Catalyst Pharma|DNLI (Denali Therapeutics Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Harmony Corp HRMY|Projected Price to Earnings BHVN (Biohaven Ltd.)|AMLX (amylyx.com) - Future Price to Earnings Multiple|Trevi Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio PRAX (Praxis Precision Medicines Inc)|Anavex Corp - Forward P/E Multiple|Future Price to Earnings Multiple CBLL (CeriBell EEG)|PRTA: Forward P/E Multiple|Projected Price to Earnings Ratio Alector (ALEC)|Future Price to Earnings Annexon|OMER: Future Price to Earnings Multiple|Forward P/E Multiple NGNE|Forward P/E Multiple AC Immune Inc (ACIU)|Future Price to Earnings Voyager Therapeutics VYGR|NMRA (neumoratx.com) - Price to Expected Earnings Ratio|Scilex - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Holdings Inc.|ACOG (alphacognition.com) - Projected Price to Earnings|Cognition Therapeutics Inc. (CGTX) - Forward P/E Multiple|Projected Price to Earnings IKT|SAVA (cassavasciences.com) - Market Cap to Future Earnings Ratio|Forward P/E Multiple ASRT|Market Cap to Projected Earnings coyatherapeutics.com|Forward P/E Multiple VTGN (Vistagen)|OVID - Projected Price to Earnings|ABOS - Future Price to Earnings|Market Cap to Projected Earnings cervomed.com CRVO|ATHE: Forward P/E Multiple|Clene (CLNN) - Forward P/E Multiple|Projected Price to Earnings PEPG|Price to Future Earnings Ratio JUNS (Jupiter Neurosciences, Inc.)|Future Price to Earnings Relmada Therapeutics (RLMD)|Market Cap to Projected Earnings annovisbio.com|Future Price to Earnings Grace Therapeutics GRCE|AIFF - Projected Price to Earnings|KLTO - Future Price to Earnings|NRSN (NeuroSense Therapeutics) - Price to Future Earnings Ratio|RVPH: Forward P/E Multiple|Projected Price to Earnings Ratio MetaVia (MTVA)|Projected Price to Earnings NRXS|Forward P/E Multiple Helius Medical Technologies Inc.|Future Price to Earnings Passage Bio, Inc. (PASG)|NEUP (bionomics.com.au) - Future Price to Earnings Multiple|Future Price to Earnings Minerva Neurosciences NERV|athira.com (ATHA) - Projected Price to Earnings Ratio|Addex Therapeutics Ltd - Forward P/E Multiple|ALZN - Forward P/E Multiple|CYCN (cyclerion.com) - Projected Price to Earnings|Price to Future Earnings Ratio PTIX|Future Price to Earnings Pasithea Therapeutics Corp|Cortigent Medical (CRGT) - Market Cap to Projected Earnings|Future Price to Earnings Avenue Therapeutics, Inc. (ATXI)|BCLI - Projected Price to Earnings Ratio|Future Price to Earnings Cara Therapeutics, Inc CARA|CHRO - Projected Price to Earnings|Eliem - Forward P/E Multiple|Projected Price to Earnings Ratio Intra-Cellular Therapies|LBPH (Longboard Pharmaceuticals, Inc.) - Projected Price to Earnings|Marinus Pharmaceuticals Inc - Future Price to Earnings Multiple|Projected Price to Earnings NKGN|NRBO (NeuroBo Pharma) - Market Cap to Future Earnings Ratio|Forward P/E Multiple SAGE|SNPX (synaptogen.com) - Future Price to Earnings Multiple|Forward P/E Multiple TRVN (Trevena)|Vigil Neuroscience Inc. (VIGL) - Projected Price to Earnings Ratio|WENA - Future Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Corp)
